|Articles|May 1, 2001

Postmenopausal estrogen therapy and ovarian cancer

Small patient numbers, weak associations, plus the mixed story in the observational studies complicate accurate interpretation of the latest epidemiologic study on ERT.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Subscribe Now!

Related Content

DARE to PLAY sildenafil cream becomes commercially available for women in select states

ByMorgan Ebert, Managing Editor

December 10th 2025

Long-term cardiovascular disease risk increased in women diagnosed with uterine fibroids

ByMorgan Ebert, Managing Editor

December 10th 2025

First-trimester metformin use linked to pregnancy outcomes in PCOS patients

ByContemporary OB/GYN Staff

December 10th 2025

Maternal thyroid imbalance linked to autism risk in offspring

ByCeleste Krewson, Assistant Editor

December 10th 2025

Brexanolone shows rapid, sustained relief in postpartum depression

ByMelanie Barrett, MD

December 9th 2025

Latest CME

Multimedia

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Rachel N. Grisham, MD; Domenica Lorusso, MD, PhD

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Jill Alldredge, MD; Emely Alfaro, MS, RN, CNS, OCN

Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Emely Alfaro, MS, RN, CNS, OCN; Jill Alldredge, MD

Video

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Danielle Nance, MD; Kimberley Youkhana, MD

Postmenopausal estrogen therapy and ovarian cancer

Newsletter

Related Content

DARE to PLAY sildenafil cream becomes commercially available for women in select states

Long-term cardiovascular disease risk increased in women diagnosed with uterine fibroids

First-trimester metformin use linked to pregnancy outcomes in PCOS patients

Maternal thyroid imbalance linked to autism risk in offspring

Brexanolone shows rapid, sustained relief in postpartum depression

Latest CME

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Trending on Contemporary OB/GYN

DARE to PLAY sildenafil cream becomes commercially available for women in select states

Long-term cardiovascular disease risk increased in women diagnosed with uterine fibroids

Justin Drake, PhD, discusses the latest research on a protein-based liquid biopsy to detect early breast cancer

Maternal thyroid imbalance linked to autism risk in offspring

First-trimester metformin use linked to pregnancy outcomes in PCOS patients